OMER: 奥麦罗制药

OMER新闻

• 05:24 Omeros: The Trade After European Rejection (NASDAQ:OMER)
• 20:35 Stock Indexes Finish Sharply Lower as Tech Stocks Plunge
• 15:13 Stock Indexes Mostly Lower as Chipmaker Weakness Persists
• 14:11 Stocks are Mixed on Rotation Out of Chipmakers and AI Stocks
• 12:02 Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
• 10:55 Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
• 10:22 Omeros Receives EMA CHMP Negative Opinion On Its Marketing Authorization Application For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
• 10:22 Omeros就其用于治疗造血干细胞移植相关血栓性微血管病的Narsoplimab上市许可申请收到EMA CHMP负面意见
• 10:43 Cantor Fitzgerald重申对Omeros的“增持”评级，维持22美元目标价
• 10:43 Cantor Fitzgerald Reiterates Overweight on Omeros, Maintains $22 Price Target
• 18:47 This 3M Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
• 20:29 Dow Jones Futures: Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals
• 17:51 Omeros Transplant Drug Could Be Bigger than Expected, Says Analyst
• 17:51 欧美罗士移植药物可能比预期更大，分析师表示
• 10:39 Cantor Fitzgerald Upgrades Omeros to Overweight, Announces $22 Price Target
• 10:39 康特菲茨杰拉德公司将Omeros股票评级提升至超重，宣布目标股价为22美元
• 16:00 What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
• 13:55 Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?
• 14:28 Making Drugs With AI: Biopharma Giants Gear Up For New Arena
• 12:45 Omeros: YARTEMLEA Is Off To A Blistering Start (NASDAQ:OMER)
• 14:35 This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why